Ciclopirox Market Research Report By Application (Tinea Cruris (jock itch), Tinea Pedis (athlete's foot), Tinea Unguium (onychomycosis), Tinea Corporis (ringworm), Tinea Versicolor (pityriasis versicolor)), By Drug Type (Cream, Gel, Nail Polish, Solution, Shampoo), By Form (Topical, Oral), By Route of Administration (Topical, Oral) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032

Ciclopirox Market Overview

As per MRFR analysis, the Ciclopirox Market Size was estimated at 0.42 (USD Billion) in 2022. The Ciclopirox Market Industry is expected to grow from 0.44 (USD Billion) in 2023 to 0.67 (USD Billion) by 2032. The Ciclopirox Market CAGR (growth rate) is expected to be around 4.89% during the forecast period (2024 - 2032).

Key Ciclopirox Market Trends Highlighted

Ciclopirox is an antifungal medication used to treat a variety of skin infections. It is available in both topical and oral forms. The topical form is applied directly to the affected area, while the oral form is taken by mouth.

Ciclopirox works by inhibiting the growth of fungi. Key market drivers for ciclopirox include the rising prevalence of fungal infections and the increasing demand for effective antifungal treatments.

Opportunities to be explored in the ciclopirox market include the development of new and improved formulations and the expansion into new markets. In recent times, the market has witnessed significant growth due to the increasing awareness of fungal infections and the availability of effective treatment options.

Key trends in the ciclopirox market include the growing popularity of topical formulations, the increasing use of oral formulations for systemic infections, and the development of new drug delivery systems.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Ciclopirox Market Drivers

Rising Prevalence of Fungal Infections

Fungal infections are a major global health concern, affecting millions of people worldwide. The rising prevalence of these infections is primarily due to factors such as increasing antibiotic use, weakened immune systems, and the emergence of new and resistant fungal strains.

Ciclopirox, with its broad-spectrum antifungal activity and minimal side effects, is a valuable treatment option for various fungal infections, including onychomycosis, tinea pedis, and tinea corporis.

The growing incidence of these infections is expected to drive the demand for ciclopirox in the coming years.

Increasing Awareness and Diagnosis of Fungal Infections

Traditionally, fungal infections have been underdiagnosed and undertreated due to a lack of awareness and limited access to diagnostic tools. However, recent advances in diagnostic techniques, such as PCR and culture-based methods, have improved the accuracy and speed of fungal identification.

This increased awareness and improved diagnosis are leading to a greater number of patients being diagnosed with fungal infections, subsequently driving the demand for effective treatment options like ciclopirox.

Technological Advancements in Drug Delivery

Ongoing advancements in drug delivery systems are enhancing the efficacy and convenience of ciclopirox treatment. Novel formulations, such as nanocarriers, liposomes, and micelles, are being developed to improve drug penetration, reduce side effects, and enhance patient compliance.

These advancements are expected to expand the application of ciclopirox in the treatment of various fungal infections and contribute to the growth of the Global Ciclopirox Market Industry.

Ciclopirox Market Segment Insights:

Ciclopirox Market Application Insights

Application Segment Insights and Overview The application segment plays a crucial role in shaping the dynamics of the Global Ciclopirox Market. Among the various applications, Tinea Cruris (jock itch), Tinea Pedis (athlete's foot), Tinea Unguium (onychomycosis), Tinea Corporis (ringworm), and Tinea Versicolor (pityriasis versicolor) hold significant market shares.

Tinea Cruris, commonly known as jock itch, is a fungal infection that affects the groin area. The Global Ciclopirox Market for Tinea Cruris treatment is projected to witness substantial growth owing to the rising prevalence of the infection, particularly among athletes and individuals engaged in physical activities.

Tinea Pedis, also known as athlete's foot, is another prevalent fungal infection that affects the feet. The Global Ciclopirox Market for Tinea Pedis treatment is anticipated to expand at a steady pace, driven by increasing awareness about foot hygiene and the availability of effective topical treatments.

Tinea Unguium, commonly referred to as onychomycosis, is a fungal infection of the toenails or fingernails. The Global Ciclopirox Market for Tinea Unguium treatment is expected to exhibit moderate growth, primarily due to the chronic nature of the infection and the need for prolonged treatment regimens.

Tinea Corporis, commonly known as ringworm, is a fungal infection that affects the skin on various parts of the body. The Global Ciclopirox Market for Tinea Corporis treatment is projected to grow at a moderate pace, driven by the increasing incidence of skin infections and the efficacy of ciclopirox in treating these conditions.

Tinea Versicolor, also known as pityriasis versicolor, is a common fungal infection of the skin that causes discolored patches. The Global Ciclopirox Market for Tinea Versicolor treatment is anticipated to witness steady growth, supported by the increasing prevalence of the infection and the availability of effective topical treatments.

Overall, the application segment of the Global Ciclopirox Market is highly competitive, with several players offering a wide range of products. The market is expected to continue to grow in the coming years, driven by the rising prevalence of fungal infections and the increasing demand for effective treatments.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Ciclopirox Market Drug Type Insights

The Global Ciclopirox Market is segmented by Drug Type into Cream, Gel, Nail Polish, Solution, and Shampoo. The Cream segment held the largest market share in 2023, accounting for around 40% of the Global Ciclopirox Market revenue.

The Gel segment is projected to be the fastest-growing segment during the forecast period, with a CAGR of 5.5% from 2024 to 2032. The growth of the Gel segment can be attributed to the increasing prevalence of fungal infections and the ease of application of gels. The Solution segment is also expected to witness significant growth during the forecast period, with a CAGR of 4.8%.

The growth of the Solution segment can be attributed to the increasing demand for non-prescription topical antifungal solutions for the treatment of mild fungal infections. The Nail Polish segment is expected to hold a steady market share during the forecast period, with a CAGR of 4.0%. The Shampoo segment is expected to have a CAGR of 3.5% during the forecast period.

Ciclopirox Market Form Insights

The Global Ciclopirox Market is segmented by form into topical and oral. Topical Ciclopirox is projected to hold a significant market share due to its extensive use in treating fungal skin infections. In 2023, the topical segment held a dominant market share of around 80%, and it is anticipated to maintain its dominance throughout the forecast period.

The growth of the topical segment can be attributed to the ease of application, fewer side effects, and widespread availability of topical formulations. On the other hand, the oral segment is expected to witness a steady growth rate during the forecast period.

Oral Ciclopirox is primarily used for treating systemic fungal infections and is often preferred when topical treatment is not effective or feasible.

Ciclopirox Market Route of Administration Insights

The Global Ciclopirox Market is segmented based on the Route of Administration into Topical and Oral. The Topical segment held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period.

The growth of the Topical segment can be attributed to the increasing prevalence of fungal infections, such as athlete's foot and ringworm, which are commonly treated with topical ciclopirox.

The Oral segment is expected to witness a significant growth rate during the forecast period due to the rising incidence of systemic fungal infections, such as candidiasis and aspergillosis, which require oral administration of ciclopirox.

Ciclopirox Market Regional Insights

Regionally, North America dominated the market, accounting for a significant share of the global revenue in 2023. Europe is anticipated to follow North America, with a considerable market size. APAC is projected to witness the fastest growth rate during the forecast period, driven by increasing demand from emerging economies such as China and India.

South America and MEA are expected to contribute steadily to the overall market growth. The market growth is attributed to the rising prevalence of fungal infections, increasing awareness about ciclopirox, and the launch of new products.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Ciclopirox Market Key Players and Competitive Insights:

Major players in the Ciclopirox Market industry are constantly engaging in research and development to enhance their product offerings and gain a competitive edge. Leading Ciclopirox Market players are focusing on developing innovative products that meet the evolving needs of customers.

The Ciclopirox Market development includes the introduction of new products, the expansion of existing product lines, and the acquisition of other companies. The competitive landscape of the Ciclopirox Market is expected to remain dynamic over the forecast period, with major players continuing to compete on factors such as product quality, innovation, and cost-effectiveness.

A leading company in the Global Ciclopirox Market is Bausch Health Companies Inc. The company's strong brand recognition, extensive distribution network, and focus on research and development have contributed to its success in the market.

Bausch Health Companies Inc. offers a range of Ciclopirox products, including topical solutions, creams, and ointments. The company's products are marketed under various brand names, such as Loprox and Penlac. Bausch Health Companies Inc. has a strong presence in North America and Europe, and the company is also expanding its presence in emerging markets.

Another major player in the Global Ciclopirox Market is Taro Pharmaceutical Industries Ltd. The company's strengths include its low-cost manufacturing capabilities, its strong product portfolio, and its extensive distribution network.

Taro Pharmaceutical Industries Ltd. offers a range of Ciclopirox products, including topical solutions, creams, and ointments. The company's products are marketed under various brand names, such as Ciclodan and Ciclopirox-T. Taro Pharmaceutical Industries Ltd. has a strong presence in North America and Europe, and the company is also expanding its presence in emerging markets.

Key Companies in the Ciclopirox Market Include:

• Glenmark Pharmaceuticals Ltd.


• Lupin Lifesciences Inc.


• Apotex Inc.


• Valeant Pharmaceuticals International, Inc.


• Novartis AG


• Taro Pharmaceutical Industries Ltd


• Sun Pharmaceutical Industries Ltd


• Dermira, Inc.


• Teva Pharmaceutical Industries Ltd


• Mylan N.V.


• Sanofi Aventis


• Cipla Ltd.


• Hikma Pharmaceuticals PLC


• Luye Pharma Group


• Bayer AG

Ciclopirox Market Industry Developments

The increasing prevalence of fungal infections, rising awareness about Ciclopirox, and the launch of new products are key factors driving market growth.

Recent developments include the approval of Luzu's topical Ciclopirox solution for the treatment of onychomycosis in 2023 and the acquisition of Taro Pharmaceuticals by Hikma Pharmaceuticals in 2022, strengthening Hikma's position in the antifungal market.

The market is expected to witness continued growth due to the increasing demand for effective antifungal treatments and the development of new formulations and delivery systems.

Ciclopirox Market Segmentation Insights

• Ciclopirox Market Application Outlook


• Tinea Cruris (jock itch)


• Tinea Pedis (athlete's foot)


• Tinea Unguium (onychomycosis)


• Tinea Corporis (ringworm)


• Tinea Versicolor (pityriasis versicolor)


• Ciclopirox Market Drug Type Outlook


• Cream


• Gel


• Nail Polish


• Solution


• Shampoo


• Ciclopirox Market Form Outlook


• Topical


• Oral


• Ciclopirox Market Route of Administration Outlook


• Topical


• Oral


• Ciclopirox Market Regional Outlook


• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa